A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT06199505

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06199505
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06199505. Randomized; no masking; primary purpose treatment. Start 2023-11-21 (actual); primary completion 2024-06-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
Intervention (Drug)
GZR101
Intervention (Drug)
insulin degledec/insulin aspart
Lead sponsor
Gan and Lee Pharmaceuticals, USA (class: industry)

Record details

Record id
cardio:ct-nct06199505
Content hash
4d4cdad1d7f40e2856c63c6c42cca9db81609fe57149e06972f71d7a4c8c7d64